Adverse Effects of Macrolide Antibacterials

Drug Safety

Volumn 9, Issue 5, 1993, Pages 346-364

  Periti, Piero ^a,b   Mazzei, Teresita ^a   Mini, Enrico ^a   Novelli, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Dipartimento di Farmacologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DIRITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN ACISTRATE; ERYTHROMYCIN ESTOLATE; ERYTHROMYCIN PROPIONATE; FLURITHROMYCIN; JOSAMYCIN; MACROLIDE; MIDECAMYCIN; MIOKAMYCIN; ROKITAMYCIN; ROXITHROMYCIN; SPIRAMYCIN; TROLEANDOMYCIN;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADOLESCENT; ADULT; AGED; ANAPHYLACTOID PURPURA; ASTHMA; AUTOIMMUNE HEMOLYTIC ANEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHOLESTATIC HEPATITIS; DELAYED HYPERSENSITIVITY; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ESOPHAGITIS; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HEART DISEASE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC PYLORUS STENOSIS; HYPOTHERMIA; IMMEDIATE TYPE HYPERSENSITIVITY; INTERSTITIAL NEPHRITIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; LIVER TOXICITY; MALE; MENTAL DISEASE; MYASTHENIA GRAVIS; NAUSEA; ORAL DRUG ADMINISTRATION; OTOTOXICITY; REVIEW; SIDE EFFECT; TINNITUS; VOMITING;

ANTIBIOTICS, MACROLIDE; ARRHYTHMIA; DRUG HYPERSENSITIVITY; GASTROINTESTINAL DISEASES; HEARING; HUMAN;

EID: 0027436439     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199309050-00004     Document Type: Review

References (132)

1. Ototoxic reaction to erythromycin
2. Pseu-domembranous colitis associated with ampicillin and erythromycin therapy: report of a case
3. Which salt of erythromycin is most hepatotoxic?
4. The future role and importance of macrolides
5. Ototoxicity of erythromycin gluceptate
6. QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant
7. An evaluation of tolerance of roxithromycin in adults
8. Ricerca multicentrica sulla efficacia e tollerabilità nell’adulto e nel bambino della josamicina
9. Hepatotoxicity of erythromycin
10. Minireviews. Vancomycin- and eryth-romycin-induced hearing loss in humans
11. Biliary excretion of erythromycin after parenteral administration
12. Psychiatric complications with erythromycin
13. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues
14. Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin
15. Asthma due to inhaled chemical agents — the macrolide antibiotic spiramycin
16. Anemia emolitica immunitaria farmacoindotta in un paziente di 18 mesi. Agente responsabile: eritromicina
17. Spiramycin: safety in man
18. Irreversible sensorineural hearing loss due to erythromycin
19. Partial deafness after erythromycin
20. Adverse reactions to erythromycin
21. Prospective comparison of patient tolerance to enteric-coated vs nonenteric-coated erythromycin
22. Nefritis intersticial aguda por eritromicina
23. The macrolide revival: thirty-five years after erythromycin
24. Erythromycin ‘free base’ — a nonsensitizing topical antibiotic for infected dermatoses and acne vulgaris
25. Fixed eruption due to erythromycin
26. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds
27. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome
28. Hépatites dues a divers dérivés de l’érythromycine
29. Pseudomem-branous colitis associated with erythromycin
30. Fulminant hepatic failure associated with intravenous erythromycin lactobionate
31. Cholestatic hepatitis caused by esters of erythromycin and oleandomycin
32. Torsades de pointes induites par l’association lidocaine-erythromycine et insuffisance hépatique
33. QT prolungation and recurrent ‘torsades de pointes’ during erythromycin lactobionate infusion
34. Erythromycin-induced pancreatitis
35. Acute pancreatitis induced by erythromycin
36. The Schönlein-Henoch syndrome: glomerulonephritis following erythromycin
37. Rokitamycin
38. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview
39. Hypothermia from erythromycin
40. Acute pancreatitis associated with infusion of erythromycin lactobionate
41. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports
42. Influence of erythromycin on the normal human flora and colonization of the oral cavity, throat and colon
43. The electromyographic changes induced by antibiotics: a preliminary study
44. Erythromycin-induced dynamic ileus?
45. Intestinal secretion of erythromycin base
46. Clinical toleration and safety of azithromycin
47. Hépatotoxicité des médicaments anti-infectieux. Première partie: les antibiotiques anti-bactériens
48. Erythromycin estolate and jaundice
49. Recently described adverse reactions to antimicrobials
50. Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract
51. Effect of rokitamycin on upper gastrointestinal contractile activity. Analysis of side-effects on gastrointestinal tract
52. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog
53. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut
54. Review of clinical experience with midecamycin in France
55. Efficacy and safety of roxithromycin in treating paediatric patients. A European multicentre study
56. Oto-toxicité de l’érithromycine au cours de l’insuffisance rénale chronique
57. Surdité transitoire chez des insuffisants rénaux traités par l’érythromycine
58. Fixed drug eruptions in children: a series of 23 cases with provocative tests
59. New macrolides: expanded horizons for an old class of antibiotics
60. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy
61. Toxic epidermal necrolysis due to erythromycin
62. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis
63. Propionyl erythromycin. A review of 20,252 case reports for side effect data
64. Prolonged cholestasis after trolenadomycin-induced acute hepatitis
65. Hépatites au cours de l’antibiothérapie. Bilan rétrospectif de l’Association des Centres de Pharmacovigilance et du Bureau de la Pharmaco-vigilance D.P.H.M., Ministère de la Santé
66. Effect of erythromycin on the oro-caecal transit time in man
67. Hepatic safety of erythromycin acistrate in 1549 patients with respiratory tract or skin infection
68. Irreversible ototoxic effect of erythromycin
69. Torsades de pointes associated with antimicrobial therapy for pneumonia
70. Delayed hypersensitivity to erythromycin
71. Ototoxicity of erythromycin lactobionate
72. The renaissance of erythromycin
73. Adverse antibiotic effects associated with renal insufficiency
74. Study serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection
75. Aggravation of myasthenia gravis by erythromycin
76. A survey of the side effects of midecamycin acetate (Miocamycin) dry syrup after marketing
77. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin
78. Ototoxicity of erythromycin in patients with renal insufficiency
79. Erythromycin-induced ototoxicity
80. Transient perceptive deafness due to erythromycin lactobionate
81. Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics
82. Bullous fixed drug eruption presumably due to erythromycin
83. Comparative study on effects of 14- and 16-membered macrolides on gastrointestinal motility in unanaesthetized dogs
84. Clinical evaluation of midecamycin
85. Erythromycin-induced immune hemolytic anemia
86. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism
87. The development of macrolides: clarithromycin in perspective
88. New macrolide antibiotics: azithromycin and clarithromycin
89. Immune mechanisms in drug-induced liver injury
90. Gastrointestinal motor-stimulating activity of macrolide antibiotics and the structure-activity relationship
91. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections
92. Erythromycin rash in glandular fever
93. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states Part I–II
94. Pharmacokinetic drug interactions of macrolides
95. Esophagite ulcérée après prise de spiramycine
96. Drug interactions and hepatitis produced by some macrolide antibiotics
97. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential
98. Fixed drug eruption to erythromycin
99. Macrolides and gastrointestinal motility
100. Alterations in gastrointestinal motility associated with erythromycin
101. Etude électrophysiologique des effets pro-arythmogènes de l’érythromycine
102. Pseudomembranous colitis: a case report and literature review
103. Drug-induced liver disease
104. Les macrolides aujourd’hui. Leur large utilisation en pratique courante est justifiée
105. La josamicina nel trattamento dell’acne volgare. Risultati di uno studio multicentrico su 745 pazienti
106. Comparison of the side effects and gastrointestinal motility observed after administration of erythromycin and josamycin to dogs
107. Ototoxicity of erythromycin
108. Antibiotics increase incidence of hepatitis
109. Serum glutamic oxalacetic transaminase: false elevations during administration of erythromycin
110. Erythromycin-induced hearing loss
111. Infantile hypertrophic pyloric stenosis related to ingestion of erythromycin estolate: a report of five cases
112. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation
113. Antibiotics: potential hazards to male fertility
114. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with QT prolongation (torsades de pointes)
115. Ototoxic effect of erythromycin therapy
116. Entravenous erythromycin lactobionate-induced severe nausea and vomiting
117. Safety profile of dirithromycin
118. Ototoxicity of erythromycin in peritoneal dialysis patients
119. Pancréatite aigue associée à une antibiothérapie par l’érythromycine intraveineuse
120. Hepatic dysfunction and jaundice in patients receiving triacetyloleandomycin
121. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction
122. Immediate- and delayed-type allergy to erythromycin
123. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (second of two parts)
124. Erythromycin ototoxicity: a call to heighten recognition
125. Erythromycin: a case of nightmares
126. Erythromycin-induced hemolytic anemia
127. The tolerance and toxicity of clarithromycin
128. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy
129. Cholestatic and hepatocellular injury associated with erythromycin esters: a report of 9 cases
130. Effects of erythromycin on gastrointestinal tract motility
131. Erythromycin and gastrointestinal motility